FundingMachineCheck programme rules

Funding Atlas: life-science capital intelligence

Life-science funding, mapped.

Dot-matrix world map with current programme signals for 14 country funder jurisdictions. European Union and Global records are listed separately.
Programmes
88
Jurisdictions
15
Funders
65
Deadlines ahead
47

Source snapshot as of . The jurisdiction figure excludes Global. European Union records are listed separately rather than at an invented country point.

Browse source records by funder jurisdiction

Country signals describe the funder jurisdiction. They do not describe applicant eligibility or applicant location.

Austria (5 programmes)
  1. Austrian Life Sciences 2024 to 2026: clinical studies (Phase I and II) FFG (Austrian Research Promotion Agency)
  2. aws Guarantee - Equity Leverage (current specific terms; historical Double Equity) aws (Austria Wirtschaftsservice)
  3. Basisprogramm (general programme) FFG
  4. Clinical research programme (KLIF) FWF (Austrian Science Fund)
  5. Innovation (2024-2026) Vienna Business Agency (Wirtschaftsagentur Wien)
Australia (5 programmes)
  1. Cooperative Research Centres Projects (CRC-P) Department of Industry
  2. International Clinical Trial Collaborations Medical Research Future Fund, Clinical Trials Activity Initiative
  3. MRFF grant opportunities (Million Minds Mental Health Research Mission; Clinical Trials Activity Initiative including International Clinical Trial Collaborations) Medical Research Future Fund
  4. R&D Tax Incentive Australian Taxation Office and AusIndustry
  5. Venture investment in biomedical technologies associated with Brandon BioCatalyst Member Institutes Brandon BioCatalyst (formerly the Medical Research Commercialisation Fund), managed by Brandon Capital
Canada (3 programmes)
  1. Accelerate (industry-matched research internships) Mitacs
  2. NRC IRAP advisory services and funding National Research Council of Canada
  3. Project Grant Canadian Institutes of Health Research
Switzerland (1 programmes)
  1. Patent box and additional R&D deduction (cantonal) Swiss cantons
Germany (5 programmes)
  1. Clinical Trials Programme (investigator-initiated clinical trials) Deutsche Forschungsgemeinschaft (DFG)
  2. Forschungszulage (research allowance) German Federal Government
  3. ForTra Translational Research Else Kroener-Fresenius-Stiftung
  4. KMU-innovativ: Biomedizin German Federal Ministry of Research, Technology and Space (BMFTR, formerly BMBF), through Projektträger Jülich
  5. KMU-innovativ: Medizintechnik German Federal Ministry of Research, Technology and Space (BMFTR)
Denmark (1 programmes)
  1. LF Fellows Lundbeck Foundation
France (1 programmes)
  1. PRCE collaborative research projects between public labs and companies Agence Nationale de la Recherche (ANR)
Ireland (2 programmes)
  1. Disruptive Technologies Innovation Fund (DTIF) - Call 8 Department of Enterprise, Tourism and Employment (DETE), administered by Enterprise Ireland
  2. R&D Corporation Tax Credit Irish Revenue
Netherlands (3 programmes)
  1. Geneesmiddelen VIMP 2026-1 (under Goed Gebruik Geneesmiddelen (GGG)) ZonMw
  2. Innovatiekrediet (Innovation Credit) RVO
  3. Innovation box (reduced corporate tax on qualifying innovation profits) Dutch Tax Administration
Norway (1 programmes)
  1. Innovation project in the industrial sector: Energy and transport 2026 Research Council of Norway
Poland (1 programmes)
  1. R&D relief (ulga B+R) Polish Ministry of Finance
Singapore (1 programmes)
  1. Startup SG Tech (proof of concept and proof of value grants) Enterprise Singapore
United Kingdom (10 programmes)
  1. Efficacy and Mechanism Evaluation (EME) NIHR and MRC
  2. Future Fund: Breakthrough (equity co-investment) British Business Bank
  3. Innovative Licensing and Access Pathway (Innovation Passport) MHRA
  4. Invention for Innovation (i4i) Product Development Awards NIHR
  5. Knowledge Transfer Partnerships Innovate UK
  6. MRC Impact Acceleration Award (formerly the MRC Gap Fund) Medical Research Council (UKRI)
  7. MRC Proof of Concept (formerly the Developmental Pathway Funding Scheme) Medical Research Council
  8. Patent Box HM Revenue and Customs
  9. R&D tax relief: Enhanced R&D Intensive Support (ERIS) for loss-making R&D-intensive SMEs, and the merged scheme (RDEC) HM Revenue and Customs
  10. Rare Disease Clinical Trials Programme LifeArc
United States (28 programmes)
  1. Alcohol and Substance Use Disorders Research Program (ASUDRP) CDMRP
  2. Alzheimer's Association Research Grant For All (AARGA) Program Alzheimer's Association
  3. Alzheimer's Research Program (AZRP; formerly PRARP) CDMRP
  4. America's Seed Fund (SBIR/STTR) National Science Foundation
  5. Autism Research Program (ARP) CDMRP
  6. Broad Pragmatic Studies (BPS) PCORI Funding Announcement - Cycle 1 2027 PCORI
  7. Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (RFA-FD-25-020, R01) FDA Office of Orphan Products Development
  8. Clinical Trial (CLIN2) Awards California Institute for Regenerative Medicine
  9. Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed) NIH NCATS
  10. Collaborative research on Huntington's disease CHDI Foundation
  11. Core Facility Support Award (RFA R-27.2-CFSA) Cancer Prevention and Research Institute of Texas
  12. Drug Development RFP (venture philanthropy / mission-related investment) Alzheimer's Drug Discovery Foundation
  13. Efficient and Innovative Natural History Studies in Rare Diseases (RFA-FD-25-017) FDA Office of Orphan Products Development
  14. Epilepsy Research Program (ERP) CDMRP
  15. Federal research credit (Section 41) with payroll-tax offset for qualified small businesses Internal Revenue Service
  16. Health Science Futures (HSF) Mission Office Innovative Solutions Opening (ISO), ARPA-H-SOL-24-104 (Amendment 03) ARPA-H
  17. NeuroNEXT (Phase 2 clinical trials network in neurology) NIH NINDS
  18. New Ideas - Request for Applications Simons Foundation Autism Research Initiative
  19. PAR-25-180 Industry-academic partnerships for pharmacological interventions (U01) NIH NIMH
  20. PAR-25-183 Confirmatory efficacy trials (R33) NIH NIMH
  21. PAR-25-184 Clinical trials to test the therapeutic potential of pharmacological interventions (R61/R33) NIH National Institute of Mental Health
  22. PAR-25-446 Clinical trials of medications for substance use disorders (UG3/UH3) NIH National Institute on Drug Abuse
  23. Parkinson's Disease Therapeutics Pipeline Program (TPP) The Michael J. Fox Foundation
  24. Parkinson's Research Program (PRP) CDMRP
  25. Part the Cloud clinical trial funding Alzheimer's Association
  26. Peer Reviewed Medical Research Program (PRMRP): Clinical Trial Awards and others CDMRP (Department of Defense)
  27. Policy note: foreign subawards not permitted from 1 May 2025 (NOT-OD-25-104); international project components (NOT-OD-25-155) NIH
  28. Traumatic Brain Injury and Psychological Health Research Program (TBIPHRP) CDMRP

European Union and Global records

European Union source records (20 programmes)
  1. EIC Accelerator (grant up to EUR 2.5m plus investment up to EUR 10m; EUR 15m for strategic technologies) European Innovation Council
  2. EIC Pathfinder Open and Pathfinder Challenges (2026 challenge topics include Biotechnology for Healthy Ageing) European Innovation Council
  3. EIC STEP Scale Up European Innovation Council
  4. EIC Transition European Innovation Council
  5. ERC Proof of Concept European Research Council
  6. EU4Health - Capacity reservation for personal protective equipment pilot (EU FAB+ PPE pilot) European Health and Digital Executive Agency (HaDEA) / European Commission
  7. Eurostars Call 12 (national co-funding through each country's agency) Eureka, Eurostars 3
  8. HORIZON-HLTH-2026-01-IND-03 regulatory science to support translational development of patient-centred health technologies European Commission, Horizon Europe Cluster 1
  9. HORIZON-HLTH-2027-01-CARE-02 personalised approaches to reduce risks from adverse drug reactions due to multiple medications European Commission, Horizon Europe Cluster 1
  10. HORIZON-HLTH-2027-01-DISEASE-05 novel small-molecule antiviral therapeutics for pathogens with epidemic potential European Commission, Horizon Europe Cluster 1
  11. HORIZON-HLTH-2027-01-DISEASE-08 innovative antimicrobials against antimicrobial-resistant pathogens European Commission, Horizon Europe Cluster 1
  12. HORIZON-HLTH-2027-01-DISEASE-10 prevention and management of chronic non-communicable diseases in children and young people (GACD) European Commission, Horizon Europe Cluster 1
  13. HORIZON-HLTH-2027-01-ENVHLTH-02 integrating climate-related exposures into the human exposome European Commission, Horizon Europe Cluster 1
  14. HORIZON-HLTH-2027-01-IND-01 cell-free protein synthesis platforms for discovery and production of biologicals European Commission, Horizon Europe Cluster 1
  15. HORIZON-HLTH-2027-01-STAYHLTH-01 addressing disabilities through the life course to support independent living and inclusion European Commission, Horizon Europe Cluster 1
  16. HORIZON-HLTH-2027-02-DISEASE-01 innovative interventions for non-communicable diseases European Commission, Horizon Europe Cluster 1
  17. HORIZON-HLTH-2027-02-DISEASE-14 clinical trials in neurodegenerative diseases European Commission, Horizon Europe Cluster 1
  18. HORIZON-HLTH-2027-02-IND-02 portable and versatile point-of-care diagnostics European Commission, Horizon Europe Cluster 1
  19. HORIZON-HLTH-2027-02-TOOL-01 predictive biomarkers of disease progression and treatment response using AI for chronic non-communicable diseases European Commission, Horizon Europe Cluster 1
  20. Technology Transfer Offices & Entrepreneurship Support Call EIT Health
Global source records (1 programmes)
  1. CARB-X funding rounds for early-stage antibacterial products CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator, Boston University)

Account-free

Start with your work

Use these six fields to review the encoded programme rules. Your answers stay in this browser: they are not saved, shared or sent.

Optional company figures and local entities

These optional checks use the entity that would apply: EU SME status, undertaking in difficulty, US small-business ownership and trial prerequisites. Enter figures in euros from the last approved accounts. Share premium is separate from reserves. Nothing leaves or is stored from this page.

Existing entities you could use in:
Excluded by encoded rules (0)

Classifications and policy records

These are source records, not funding-opportunity eligibility verdicts.

Current Reference records

Confirmed on an official programme page, but not fully documented for an eligibility verdict. These records do not enter the source-checked figures, map, 90-day deadlines or funding stack.

  1. Forschungsprämie

    Programme note: Research Premium

    Austrian Federal Ministry of Finance · Current Reference · Official page checked 2026-10-03

    Individual award maximum
    Not published
    Funding type
    Tax premium/tax-account credit (credited to the taxpayer's fiscal account; not taxable).
    Who can apply
    Entrepreneurs with business income, regardless of legal form. In-house R&D must be conducted in an Austrian domestic enterprise or permanent establishment. Commissioned-R&D contractors must be EU/EEA-based research-active enterprises or institutions; applicant notification/no-double-claim conditions apply.
    Timing
    Annual calendar-year claims; statutory filing window depends on the financial year.
    Screening
    Rules not yet encoded
    Official funder page

  2. CSIRO Kick-Start vouchers

    CSIRO · Current Reference · Official page checked 2026-10-03

    Individual award maximum
    Not published
    Funding type
    Dollar-matched Kick-Start voucher applied to project costs, not a cash grant paid to the applicant; guideline says voucher funds transfer internally to CSIRO research area.
    Who can apply
    Australian-registered start-ups and SMEs meeting the size/trading criteria, holding ACN or ICN, GST-registered, and able to provide matched cash funding; international companies and Australian subsidiaries of international companies are ineligible.
    Timing
    Expressions of interest accepted year-round; no dated deadline published.
    Screening
    Rules not yet encoded
    Official funder page

  3. Scientific Research and Experimental Development tax incentive

    Programme note: SR&ED

    Canada Revenue Agency · Current Reference · Official page checked 2026-10-03

    Individual award maximum
    Not published
    Funding type
    Tax incentives: deduction against income and investment tax credit (ITC), including refundable or non-refundable credit treatment as applicable.
    Who can apply
    Corporations, individuals, trusts, and partnerships conducting SR&ED work in Canada may be eligible; partnerships allocate ITCs to eligible partners. A foreign-applicant subsidiary/local-partner requirement is not published on the reviewed pages.
    Timing
    Annual tax-year claim with claimant-specific reporting deadline; no programme-wide fixed cutoff.
    Screening
    Rules not yet encoded
    Official funder page

  4. Innosuisse innovation projects with implementation partners

    Innosuisse · Current Reference · Official page checked 2026-10-02

    Individual award maximum
    Not published
    Funding type
    Grant (the funder describes its contributions as subsidies).
    Who can apply
    Implementation partners may include SMEs, large companies, start-ups, administrative bodies, non-profit organisations, and other private/public institutions; the implementation partner must create added value in Switzerland and work with a Swiss research partner.
    Timing
    Continuous submissions; apply at least six weeks before the relevant decision meeting.
    Screening
    Rules not yet encoded
    Official funder page

  5. EIB venture debt for life-science companies

    European Investment Bank · Current Reference · Official page checked 2026-10-03

    Individual award maximum
    Not published
    Funding type
    Loan / venture debt.
    Who can apply
    Targets innovation-driven companies at commercial stage that have raised equity, demonstrate a strong business model, governance and team, and have investments in the EU; eligible R&D investment plans must be geographically located in the EU. The EIB notes a limited pre-commercial exception for technologies of strategic importance to the EU.
    Timing
    Rolling assessment; no fixed application window published.
    Screening
    Rules not yet encoded
    Official funder page

  6. IHI Call 13

    Programme note: two-stage

    Innovative Health Initiative (IHI JU) · Current Reference · Official page checked 2026-10-03

    Individual award maximum
    Not published
    Funding type
    Research and Innovation Action (RIA); IHI JU financial contribution
    Who can apply
    Legal entities based in all countries associated to Horizon Europe, including Canada, Switzerland, the UK, and South Korea, eligible under normal rules
    Timing
    Call 13: short proposals due 8 October 2026; full proposals due 21 April 2027 for eligible shortlisted applicants.
    Screening
    Rules not yet encoded
    Official funder page

  7. Research, development and piloting

    Business Finland · Current Reference · Official page checked 2026-10-03

    Individual award maximum
    Not published
    Funding type
    Grant or loan (blended funding).
    Who can apply
    Companies registered in Finland that conduct economic activity (not natural persons); the applicant must have a permanent place of business in Finland and a Finnish business ID. Not self-employed individuals or sole traders.
    Timing
    Applications are processed continuously; no future dated cutoff published.
    Screening
    Rules not yet encoded
    Official funder page

  8. Crédit d'impôt recherche

    Programme note: CIR

    French tax administration · Current Reference · Official page checked 2026-10-03

    Individual award maximum
    Not published
    Funding type
    Tax credit (crédit d’impôt)
    Who can apply
    Industrial, commercial or agricultural enterprises subject to the real tax regime, with specified exempt categories also eligible. The examined official guidance does not establish the retained foreign-applicant/subsidiary condition.
    Timing
    Annual tax-credit claim; filing timing depends on the claimant and tax regime.
    Screening
    Rules not yet encoded
    Official funder page

  9. Dementia Discovery Fund

    Programme note: DDF

    Dementia Discovery Fund (managed by SV Health Investors) · Current Reference · Official page checked 2026-10-02

    Individual award maximum
    Not published
    Funding type
    Equity investment
    Who can apply
    Not published
    Timing
    Entrepreneurs may contact DDF; no dated deadline or explicit cycle published.
    Screening
    Rules not yet encoded
    Official funder page

  10. Research and development grants

    Programme note: R&D

    Scottish Enterprise · Current Reference · Official page checked 2026-10-03

    Individual award maximum
    Not published
    Funding type
    Grant; some or all may be repayable in certain circumstances.
    Who can apply
    Businesses based in or planning to locate in Scotland, in the Scottish Enterprise area, subject to innovation, commercial-prospects, capability/resources, additionality and financial-viability criteria; sole traders and charities may not be eligible.
    Timing
    Enquiry-led route; no future dated deadline or explicit application cycle published.
    Screening
    Rules not yet encoded
    Official funder page

  11. NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award

    Programme note: PAR-25-269

    NIH National Center for Complementary and Integrative Health · Current Reference · Official page checked 2026-10-03

    Individual award maximum
    Not published
    Funding type
    Grant.
    Who can apply
    Published U.S. higher-education, nonprofit, for-profit and other eligible organisation classes; non-U.S. entities and non-U.S. components of U.S. organisations are ineligible, while eligible foreign components are allowed. Confirm applicant-specific terms in the notice.
    Timing
    Published notice timing: 20 October 2026, 5:00 pm applicant local time; notice expires 14 November 2026. This Reference is not an applicant-eligibility determination.
    Screening
    Rules not yet encoded
    Official funder page

  12. Orphan Drug Credit

    Programme note: Form 8820

    Internal Revenue Service · Current Reference · Official page checked 2026-10-03

    Individual award maximum
    Not published
    Funding type
    Tax credit, not a competitive grant.
    Who can apply
    Credit applies to qualifying clinical testing expenses subject to Form 8820 conditions, including post-designation and pre-approval/licensure timing. IRS materials do not substantiate the record’s SME/large, applicant-country, or foreign-applicant-with-subsidiary taxonomy.
    Timing
    Claimed with a tax return; no programme-specific future dated application deadline published.
    Screening
    Rules not yet encoded
    Official funder page

  13. Lundbeckfonden BioCapital

    Lundbeckfonden BioCapital · Current Reference · Official page checked 2026-10-03

    Individual award maximum
    Not published
    Funding type
    Evergreen venture capital fund / venture investment.
    Who can apply
    Life science companies; further applicant/geographic/stage criteria are not stated on this page.
    Timing
    Evergreen venture capital fund; current application deadline and explicit application-cycle status not published on the official page.
    Screening
    Rules not yet encoded
    Official funder page

Your stack

Get your funding plan

This retired form is disabled. Atlas does not send profile, shortlist or contact information from this screen. Browse programme records and their original funder sources instead.

This form is disabled and does not send information.

Dated deadlines

Check the current funder call before relying on an amount or date. A recorded individual programme maximum is not an offer, an amount available to you or an eligibility decision.

Atlas profile and shortlist entries stay in this browser. The older plan form is disabled; the homepage hosts a separate consented general enquiry.